Integrated Antibody Discovery CRO: Key Selection Criteria

Selecting an integrated antibody discovery CRO is one of the most consequential decisions a drug development team makes. The right partner determines not just the speed of early discovery, but the quality, IP ownership, and clinical readiness of every molecule that follows. These questions address the criteria that matter most when evaluating a fully integrated discovery partner.

What does “integrated” actually mean in the context of an antibody discovery CRO?

An integrated antibody discovery CRO provides a continuous, end-to-end service pathway from target validation through IND filing, without requiring the client to transfer programs between multiple vendors. Fragmented discovery, where antigen preparation, immunization, screening, engineering, and preclinical assessment are handled by separate organizations, introduces handoff risk, timeline delays, and data inconsistencies at every transition point.

Nona Biosciences operationalizes this through its Idea toward IND (I-to-I®) (Nona’s integrated end-to-end service pathway from ideation through IND filing), which spans antigen preparation, animal immunization, antibody screening, lead generation and engineering, developability assessment, and pharmacological evaluation under a single program structure.

This architecture means that data generated at each stage informs the next, rather than being reinterpreted by a new team working from a handoff document. Nona Biosciences has completed more than 300 antibody discovery programs through this structure, with 19-plus molecules reaching clinical stage. For many organizations, choosing a Target-to-IND — Integrated Antibody Discovery & Preclinical CRO is the most effective way to mitigate these risks.

What platform capabilities should a discovery CRO offer for complex modalities like bispecifics and ADCs?

Bispecific and multispecific antibody manufacturing faces a fundamental chain mispairing problem: when two different heavy chains and two different light chains are co-expressed, they can assemble into incorrect combinations, reducing yield and increasing purification complexity. Fully human heavy-chain-only antibodies (HCAbs) eliminate this problem by removing the light chain entirely, producing single-domain binders that can be combined into multispecific formats without mispairing.

Nona’s Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies) generate HCAbs through natural in vivo immune selection, using human HCAb VH gene segments. With over 20 years of platform optimization, including careful selection of HCAb VH sequences that ensure highly developable binders, HCAb Harbour Mice® provide a solid foundation for bispecific and multispecific discovery. For teams building T-cell engagers, bispecific ADCs, or dual-targeting CAR-T constructs, this structural advantage is directly relevant to downstream manufacturability.

How do I evaluate the screening platform a CRO uses, and why does it matter?

The screening platform determines how many antibody candidates are recovered, how quickly, and with what level of functional characterization. Conventional hybridoma methods typically require 2 to 3 months for clonal isolation and yield a narrower diversity of binders compared to single B-cell approaches.

Nona uses the Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation) platform, which compresses single B-cell cloning to approximately one month while enabling high-throughput recovery of diverse binders. This timeline advantage is not achieved by shortening immunization: Nona maintains a 2-month immunization protocol to ensure high-quality immune responses and measurable titers, rather than adopting accelerated 3-week protocols that produce unknown titer quality. Speed is applied at the screening stage, not at the cost of immune response quality.

Is a fully human antibody the same as a humanized antibody, and does the distinction matter for CRO selection?

A fully human antibody carries a 100% human sequence and is not the same as a humanized antibody, treating these terms as synonymous carries real consequences for immunogenicity risk and regulatory positioning. A fully human antibody carries a 100% human sequence, produced through natural in vivo immune selection in a transgenic system such as Harbour Mice®. A humanized antibody begins as a non-human sequence that is then engineered to reduce immunogenicity, but it retains residual non-human residues and carries the engineering trade-offs that come with sequence modification.

Fully human sequences are inherently compatible with human immune tolerance. Humanized sequences carry residual immunogenicity risk that must be managed through additional characterization and, in some cases, clinical monitoring. When evaluating a CRO, confirming whether the platform produces fully human or humanized antibodies is a foundational question, not a technical detail.

What IP and freedom-to-operate considerations should I evaluate when selecting an antibody discovery partner?

When selecting an antibody discovery partner, intellectual property and freedom-to-operate (FTO) considerations are just as important as scientific capabilities. The right partner should help advance your program while providing a clear framework for ownership, development rights, and future commercialization.

Organizations should seek to understand how ownership of antibodies, associated data, and program-generated inventions will be managed throughout the collaboration. Clear IP terms can help minimize uncertainty as a program progresses from discovery through preclinical development and into the clinic. It is also important to understand any licensing provisions, milestone obligations, or other commercial terms that may influence future partnering, development, or commercialization decisions.

For teams seeking an end-to-end path from discovery to IND, continuity matters. Working with a partner that can support multiple stages of development may simplify technology transfer, reduce operational complexity, and provide greater consistency across the program lifecycle. Evaluating IP considerations early helps ensure that scientific progress is supported by a commercial framework aligned with long-term development goals.

Freedom-to-operate should also be assessed as part of a broader diligence strategy involving legal and intellectual property experts. While discovery partners can provide information regarding their platforms and technologies, sponsors should ensure they have a clear understanding of any rights, restrictions, or obligations that could affect future development activities.

Nona’s integrated discovery-to-IND model is designed to support this continuity by combining antibody discovery, development, and CMC capabilities within a single workflow. Alongside scientific expertise, organizations should evaluate how a prospective partner’s IP framework, development capabilities, and operational model align with the goals of their program.

How should I assess a CRO’s AI and lead optimization capabilities?

AI-assisted lead selection is moving from an experimental feature to an expected component of integrated discovery, but the value of any AI platform depends on whether it is trained on proprietary, high-quality antibody data rather than public datasets alone. The key question is not whether a CRO has an AI tool, but what data it was built on and what specific decisions it informs.

Nona’s Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) is integrated directly into the discovery workflow, guiding the incorporation of developability-optimized sequences during lead selection. This means developability criteria, including aggregation propensity, thermal stability, and expression yield, are applied during candidate selection rather than as a late-stage filter that eliminates leads after significant investment. AI platforms that operate only at the engineering stage, after leads are already selected, provide less leverage than those embedded earlier in the workflow.

When should a team choose a CRO with functional screening capabilities over one focused purely on affinity-based selection?

Affinity-based screening identifies binders, but functional screening identifies binders that drive the biology relevant to the therapeutic mechanism. For modalities such as T-cell engagers, bispecific ADCs, and CAR-T constructs, a binder that does not perform in a functional cellular context has limited translational value regardless of its affinity measurement.

Nona’s NonaCarFx™ (Nona’s CAR-based functional screening platform) enables functional evaluation of antibody candidates in cell-based assays, extending beyond affinity ranking to assess mechanism-relevant activity. This capability is relevant not only for cell therapy programs but for any modality where the therapeutic effect depends on receptor engagement, immune cell activation, or conditional payload release. Teams building T-cell engagers or bispecific ADCs should confirm whether a CRO’s screening workflow includes functional readouts before committing to a discovery partnership.

What clinical validation signals should I look for when selecting a discovery CRO?

A CRO’s clinical track record is the most direct evidence that its discovery platforms produce molecules capable of advancing through development. Platform claims without clinical validation are difficult to evaluate objectively.

Nona Biosciences has built a portfolio of 19-plus clinical-stage molecules spanning oncology, immunology, and emerging therapeutic areas including autoimmune and neurological diseases. Validated partnerships include a strategic collaboration with AstraZeneca and a Phase 1 ADC program (MesoC2) developed with Pfizer and presented at ASCO, confirming that Harbour Mice®-derived antibodies are not only discoverable but developable and clinically translatable across multiple therapeutic areas and modalities.

Teams evaluating integrated discovery partners can explore Nona’s fully human antibody discovery services and the Idea toward IND (I-to-I®) pathway to understand how each stage of the program is structured.

For teams working on bispecific or multispecific formats, Nona’s HCAb platform overview provides detailed technical context on how fully human HCAbs address chain mispairing at the discovery stage. Additional context on AI-assisted lead selection is available in Nona’s Hu-mAtrIx™ platform page.

To discuss how Nona’s integrated discovery pathway fits a specific program, reach out to Nona’s scientific team directly at nonabio.com.

1. Tiller T. et al., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, Journal of Immunological Methods, 2008. Link

2. Weiner L.M. et al., Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nature Reviews Immunology, 2010. Link

3. Kontermann R.E. and Brinkmann U., Bispecific antibodies, Drug Discovery Today, 2015. Link

4. Muyldermans S., Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link

5. Strohl W.R., Current progress in innovative engineered antibodies, Protein and Cell, 2018. Link

6. Kaplon H. et al., Antibodies to watch in 2024, mAbs, 2024. Link

7. Spiess C. et al., Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology, 2015. Link